| Old Articles: <Older 6571-6580 Newer> |
|---|
 |
The Motley Fool
August 13, 2010
Jim Mueller |
How Well Do You Use Cash, Tenet Healthcare? The faster it can turn its cash into more cash, the better for investors.   |
The Motley Fool
August 12, 2010
Brian Orelli |
Pfizer: Strengths, Weaknesses, Opportunities, Threats Knowing them all makes it easier to judge an investment. |
The Motley Fool
August 12, 2010
Brian Orelli |
Turnaround Signal, or Just Noise on the Decline? Boston Scientific clears up an FDA warning letter -- four years later. |
The Motley Fool
August 12, 2010
David Meier |
Would Jeremy Grantham Buy Vascular Solutions? With quality numbers, I have to believe Grantham would certainly give it a good, hard look. |
The Motley Fool
August 12, 2010
Charly Travers |
Agilent's Magic Formula With an earnings yield of 59.9% and a ROA greater than 25%, Agilent Technologies meets the criteria of the screen and would be suitable for purchase by an investor following this mechanical strategy. |
The Motley Fool
August 12, 2010
Charly Travers |
Impax Laboratories' Magic Formula With an earnings yield of 46.6% and a ROA greater than 25%, Impax Laboratories meets the criteria of the screen and would be suitable for purchase by an investor following this mechanical strategy. |
The Motley Fool
August 12, 2010
Jordan DiPietro |
7 Burned-Out Drug Stocks These 5-star drug stocks have been beaten down to attractive levels. |
Fast Company
September 2010
Scott Carney |
Human Egg Sales Raise Bioethical Issues Modern fertility technology has made parenthood a possibility for thousands more people, but it has also created a lucrative - and ethically questionable - global trade in human genetic material. |
Fast Company
September 2010 |
The Global Bazaar for Human Reproductive Material IVF has given hope to millions of aspiring parents, but the wild, international inconsistency of rules on egg donation has created big disparities - and for entrepreneurs, huge opportunities. |
The Motley Fool
August 11, 2010
Brian Orelli |
Amgen Comes Up a Little Short Amgen's drug Vectibix improves survival, but not by enough. |
| <Older 6571-6580 Newer> Return to current articles. |
